HUTCHMED (China) Limited
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From HUTCHMED (China) Limited
Out of the more than 40 approvals granted to new drugs in China in 2021, domestic companies bagged around half to catch up with their multinational peers in the annual innovation scorecard.
The swift rise of China’s oncology R&D has put at least four novel applications before FDA with pivotal data generated only in China.
In a new landmark, Chinese firm BeiGene has posted greater quarterly sales of its cancer drug Brukinsa in the US than in China for the first time. Meanwhile, a growing number of innovative products developed in China are on the cusp of expansion into overseas markets.
The European Medicines Agency has added nine new products to its latest list of medicines that are under review for potential EU marketing authorization.
- Other Names / Subsidiaries
- Hutchison Whampoa
- Sinopharm Pharmaceuticals Company Limited
- Hutchison MediPharma Limited
- Hutchison China MediTech Limited